Subscribe
limbeek_kerri-ann_5715
Kerri-Ann Limbeek, partner at Desmarais and trial lead for Ravgen.
25 January 2024FeaturesBig PharmaSarah Speight

Trial-focused: Lead counsel on how a strong story helped Ravgen defeat Natera

Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Ravgen and Myriad in patent dispute over DNA testing tech
24 December 2020   Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
Biotechnology
Natera stung for $57m in prenatal screening clash
18 January 2024   Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Ravgen and Myriad in patent dispute over DNA testing tech
24 December 2020   Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
Biotechnology
Natera stung for $57m in prenatal screening clash
18 January 2024   Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.

More on this story

Americas
Ravgen and Myriad in patent dispute over DNA testing tech
24 December 2020   Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
Biotechnology
Natera stung for $57m in prenatal screening clash
18 January 2024   Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.

More features

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't